Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02228408 · ClinicalTrials.gov registry record · Phase 4
Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD
A Phase 4 study of Chronic Hemodialysis (ESRD), sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT02228408 is a Phase 4 study of Chronic Hemodialysis (ESRD) that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 17 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02228408, a Phase 4 study of Chronic Hemodialysis (ESRD), has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a pilot study designed to compare the safety and cardiovascular effects of 26 weeks of combination hydralazine/isorsorbide dinitrate therapy with placebo therapy in patients receiving chronic hemodialysis. The investigators hypothesize that treatment of chronic hemodialysis (ESRD) patients with a combination of hydralazine/isosorbide dinitrate compared with placebo is safe and that it will improve heart function as well blood flow/blood vessel supply.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Hydralazine/Isorsorbide Dinitrate
Study Locations (1)
Massachusetts
- Brigham & Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-08-28 |
| Est. Completion | 2019-05-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02228408
The ClinicalTrials.gov registry entry for NCT02228408 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Hemodialysis (ESRD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02228408 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02228408 about?
NCT02228408 is a clinical study titled "Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD". This study is a pilot study designed to compare the safety and cardiovascular effects of 26 weeks of combination hydralazine/isorsorbide dinitrate therapy with placebo therapy in patients receiving chronic hemodialysis. The investigators hypothesize that treatment of chronic hemodialysis (ESRD) pat...
What is the current status of trial NCT02228408?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 17 participants. The study started on 2017-08-28. Estimated completion is 2019-05-07.
What conditions does trial NCT02228408 study?
This clinical trial studies the following conditions: Chronic Hemodialysis (ESRD).
What interventions are being tested in trial NCT02228408?
The interventions under investigation include: Placebo (DRUG), Hydralazine/Isorsorbide Dinitrate (DRUG).
Who is sponsoring clinical trial NCT02228408?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02228408 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.